An, WeiweiHolly, Katrina J.Nocentini, AlessioImhoff, Ryan D.Hewitt, Chad. S.Abutaleb, Nader S.Cao, XufengSeleem, Mohamed N.Supuran, Claudiu T.Flaherty, Daniel P.2022-10-042022-10-042022-12-311475-6366http://hdl.handle.net/10919/112066Vancomycin-resistant enterococci (VRE), consisting of pathogenic Enterococcus faecalis and E. faecium, is a leading cause of hospital-acquired infections (HAIs). We recently repurposed the FDA-approved human carbonic anhydrase (CA) inhibitor acetazolamide (AZM) against VRE agent with the likely mechanism of action for the molecules being inhibition of one, or both, of the bacterial CA isoforms expressed in VRE. To elucidate how inhibitor binding to the enzymes relates to MIC, we further characterised the inhibition constants (K (i)) against the E. faecium alpha-CA (Ef alpha-CA) and gamma-CA (Ef gamma-CA), as well as against human CA I (hCAI) and human CA II (hCAII) to assess selectivity. We have also utilised homology modelling and molecular dynamics (MD) simulations to gain a better understanding of the potential interactions the molecules are making with the targets. In this paper, we elaborate on the SAR for the AZM analogs as it pertains to MIC and K (i) for each CA.application/pdfenCreative Commons Attribution 4.0 InternationalCarbonic anhydrase inhibitorsvancomycin-resistant Enterococcusantibioticsdrug repurposingArticle - Refereedhttps://doi.org/10.1080/14756366.2022.2092729371357582121475-6374